

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-3. (Canceled)

Claim 4. (New) A method for the treatment of chronic rhinosinusitis comprising administering to a patient in need thereof about 625 mg or about 725 mg terbinafine in free or acid addition salt form.

Claim 5. (New) A pharmaceutical composition comprising about 625 mg or about 725 mg terbinafine in free or acid addition salt form in oral dosage form, said oral dosage form selected from a tablet, minitab, powder, granule, capsule, pellet and liquid oral dosage form.

Claim 6. (New) A pack containing pharmaceutical compositions according to claim 2 arranged to be dispensed in a method of treating chronic rhinosinusitis in a mammal comprising orally administering a composition comprising about 625 mg or about 725 mg terbinafine base equivalent as hydrochloride per day, or a molar equivalent in other acid addition salt or free base form, for a duration effective to reduce the symptoms of, or treat chronic rhinosinusitis, where convenient together with instructions for use, such as a calendar pack.